Detail akcie Bristol Myers Convertible Preference online

Business Summary: Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Bristol-Myers Squibb Co revenues decreased 6% to $11.2B. Net income totaled $2.46B vs. loss of $11.91B. Revenues reflect Revlimid segment decrease of 44% to $936M, Pomalyst/Imnovid segment decrease of 24% to $659M, United States segment decrease of 7% to $7.87B, International segment decrease of 3% to $3.11B. Net Income reflects Acquired IPRD decrease of 99% to $188M (expense).